Development of 4-hexadecyl-4,7-diaza-1,10-decanedithiol (HDD) kit for the preparation of the liver cancer therapeutic agent Re-188-HDD/lipiodol.
Vinay Kumar Banka, Sung-Hyun Moon, Jae Min Jeong, Sudhakara Reddy Seelam, Yun-Sang Lee, Young Joo Kim, Dong Soo Lee, June-Key Chung
Index: Nucl. Med. Biol. 42(3) , 317-22, (2015)
Full Text: HTML
Abstract
A lipiodol solution of (188)Re-4-hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (HTDD) has been successfully developed for liver cancer therapy; however, its preparation requires a multi-step synthesis and it is characterized by a low labeling yield.We synthesized a new compound, 4-hexadecyl-4,7-diaza-1,10-decanedithioacetate (AHDD), without gem dimethyl groups to address these issues. AHDD was formulated into a kit and was labeled with (188)Re. Biodistribution study was performed using normal BALB/c mice.The kit was labeled with (188)Re with a high efficiency (98.8±0.2%). After extraction with lipiodol, the overall yield of (188)Re-HDD/lipiodol was as high as 90.2±2.6%. A comparative biodistribution study of (188)Re-HTDD and (188)Re-HDD was performed in normal mice after intravenous injection. The lungs were identified as the main uptake site due to capillary-blockage. (188)Re-HDD/lipiodol showed a significantly higher lung uptake than that of (188)Re-HTDD/lipiodol (p<0.05).The newly synthesized (188)Re-HDD/lipiodol showed improved radiolabeling yield and biodistribution results compared to (188)Re-HTDD/lipiodol, and may therefore be more suitable for liver cancer therapy.Copyright © 2014 Elsevier Inc. All rights reserved.
Related Compounds
Related Articles:
2014-09-01
[Cell. Mol. Life Sci. 71(17) , 3381-92, (2014)]
2014-09-26
[J. Chromatogr. A. 1361 , 265-76, (2014)]
2014-11-01
[J. Am. Soc. Mass Spectrom. 25(11) , 1897-907, (2014)]
2014-10-01
[Eur. J. Pharm. Biopharm. 88(2) , 406-14, (2014)]
2014-01-01
[PLoS ONE 9(10) , e109201, (2014)]